NCT06848088View on ClinicalTrials.gov

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

October 10, 2029

Study Completion Date

October 10, 2029

Conditions
Melanoma
Interventions
DRUG

Fianlimab+cemiplimab

No study drug administered in this observational study.

Trial Locations (6)

37203

Sarah Cannon Research Institute, Nashville

48202

Henry Ford Hospital, Detroit

49546

Cancer & Hematology Centers of Western Michigan, Grand Rapids

78229

South Texas Oncology And Hematology, San Antonio

90025

The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles

94115

California Pacific Medical Center, San Francisco

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY